"乳腺癌患者贫血与新辅助化疗反应"。
"Anemia and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients".
机构信息
Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
Department of Statistics, University of Innsbruck, Innsbruck, Austria.
出版信息
Cancer Invest. 2021 Jul-Aug;39(6-7):457-465. doi: 10.1080/07357907.2021.1928166. Epub 2021 May 25.
We analyzed the effect of anemia on tumor response of patients with primary invasive breast cancer (BC) receiving neoadjuvant chemotherapy (NACT). The patient collective was very homogenous; finally, 74 BC patients with identical medication and duration of NACT were enrolled. After completion of NACT, 49 patients (66.2%) had a post-NACT Hb level <12 g/dl. In the anemic group, we found a tendency of lower median tumor response compared to nonanemic patients at this time (15 versus 17 mm, retrospectively, = 0.18). Age at diagnosis significantly correlated with the difference of Hb [before initiation - after completion of NACT] (correlation coefficient = 0.40, < 0.001).
我们分析了贫血对接受新辅助化疗（NACT）的原发性浸润性乳腺癌（BC）患者肿瘤反应的影响。患者群体非常同质；最终，纳入了 74 名接受相同药物和 NACT 持续时间的 BC 患者。NACT 完成后，49 名患者（66.2%）的 post-NACT Hb 水平<12g/dl。在贫血组中，我们发现此时与非贫血患者相比，中位肿瘤反应有降低的趋势（15 毫米与 17 毫米，回顾性分析， = 0.18）。诊断时的年龄与 Hb 的差异显著相关[起始前 - NACT 完成后]（相关系数=0.40， < 0.001）。
Zotero 插件